Managing Toxicities of CAR-T in Multiple Myeloma (MM) – Drs. Caitlin Costello & Joshua Richter

In this informative episode we dived into the world of CAR T-cell therapies for multiple myeloma. In this ToxCheck episode, we focused on the available CAR-T options, including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), and discussed their side effects, management strategies, and the importance of patient education.We were joined by myeloma specialists Caitlin Costello, MD, from UC San Diego Health, and Joshua Richter, MD, from Mount Sinai, who shared their insights on the acute and chronic side effects associated with CAR-T therapies. Learn about the common toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), as well as the role of prophylactic treatments and the importance of bridging therapy.This episode emphasized the critical collaboration between community oncologists and academic institutions to ensure patients receive the best care possible. Tune in to understand how to navigate the complexities of CAR-T therapies and empower your patients with the knowledge they need.Key Topics: Overview of CAR-T therapies for multiple myelomaCommon side effects: CRS and ICANSManagement strategies for acute and chronic toxicitiesThe role of prophylactic treatmentsImportance of communication between community and academic oncologistsListen us on:Apple Podcast:https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966Follow us on social media:X/Twitter: https://x.com/oncbrothers⁠Instagram: https://www.instagram.com/oncbrothersWebsite: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!#CARTtherapy, #MultipleMyeloma, #CRS, #ICANS,#OncologyBrothers